Introduction
Almost 25 centuries ago, Hippocrates proclaimed, 'Food be thy medicine and medicine be thy food.' According to a recent report by Newman et al., as many as 65% (48 out of 74) of formally synthetic drugs in the antihypertensive medicine are plant based (Newman et al., 2003) . Zerumbone (2,6,9,9-tetramethyl-[2E,6E, 10E]-cycloundeca-2,6,10-trien-1-one; Figure 1 ) was first isolated in 1956 from the essential oil of rhizomes of a wild ginger, Zingiber zerumbet Smith, which is widespread in Southeast Asia (Dev, 1956; Kitayama et al., 1999) . Over the years, a wide variety of activities have been assigned to this compound (Ozaki et al., 1991; Murakami et al., 1999 Murakami et al., , 2002 Murakami et al., , 2003a Murakami et al., , 2004 Tanaka et al., 2001; Kirana et al., 2003) . For instance, zerumbone has been found to suppress the proliferation of colon cancer (Murakami et al., 2002; Kirana et al., 2003) and breast cancer (Kirana et al., 2003) , with minimal effects on normal cells (Murakami et al., 2002) . Zerumbone has also been shown to suppress inflammation (Ozaki et al., 1991) , suppress the initiation and promotion of skin tumors in mice (Murakami et al., 2004) , and prevent azoxymethane-induced aberrant crypt foci formation in rats (Tanaka et al., 2001) . This terpenoid has also been shown to suppress dextran sodium sulfate-induced colitis in mice (Murakami et al., 2003a) and inhibit the activation of the phorbol ester-induced Epstein-Barr virus (Murakami et al., 1999) . Additional activities assigned to zerumbone are the suppression of superoxide and nitric oxide generation (Murakami et al., 2003c) and the downregulation of cyclooxygenase-2 (COX-2) (Murakami et al., 2003b) , interleukin-1b (IL1b) (Murakami et al., 2003a) , and tumor necrosis factor (TNF) (Murakami et al., 2002 (Murakami et al., , 2003a . Several of these activities could be explained if zerumbone downregulates nuclear factor-kB (NF-kB) activation, since zerumbone has proven effects on related activities.
Several genes are regulated by transcription factor NF-kB (Duyao et al., 1992; van de Stolpe et al., 1994; Yamamoto et al., 1995; Xu et al., 1996; Chu et al., 1997; You et al., 1997; Stehlik et al., 1998; Grumont et al., 1999; Guttridge et al., 1999; Schwenzer et al., 1999; Zong et al., 1999; Catz and Johnson, 2001 ; Kreuz et al., 2001; Zhu et al., 2001; Esteve et al., 2002; Morris et al., 2003) . These include genes that mediate proliferation (cyclin D1 and c-Myc), antiapoptosis (survivin, TNF receptor-associated factor 1 (TRAF1), cellularFas-associated death domain protein (FADD)-like IL-1b-converting enzyme-inhibitory protein (c-FLIP), Zerumbone enhances chemotherapeutic agent-induced cytotoxicity. In total, 10 000 cells were seeded in triplicate in 96-well plates. The cells were pretreated with 5 mM zerumbone and then incubated with the indicated concentrations of TNF (b1), doxorubicin (b2), or cisplatin (b3), for 24 h. Cell viability was then analysed by the MTT method as described in Experimental Procedures. Results are set untreated control as O. a P>0.1, b Po0.005, c Po0.001. The results were the mean7s.d. of triplicated experiments. (C) Cells were pretreated with 25 mM zerumbone for 12 h and then incubated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared, subjected to SDS-PAGE, and blotted with an anti-PARP antibody. The results shown are representative of three independent experiments. (D) Cells were pretreated with 50 mM zerumbone for 12 h and then incubated with 1 nM TNF for 16 h. The cells were incubated with a fluorescein isothiocyanate-conjugated annexin V antibody and then analysed by flow cytometry as described in Experimental procedures. The results shown are representative of two independent experiments. (E) Cells were pretreated with 50 mM zerumbone for 12 h and then incubated with 1 nM TNF for 16 h. The cells were fixed, stained with a TUNEL assay reagent, and then analysed by flow cytometry as described in Experimental procedures. The results shown are representative of two independent experiments Zerumbone inhibits NF-jB and NF-jB-mediated gene expression Y Takada et al inhibitor-of-apoptosis protein (IAP), X-chromosomelinked IAP (XIAP), Bcl-2, and Bcl-x L ), immune modulation (chemokines and interleukins), metastasis (COX-2, matrix metalloproteinase-9 (MMP-9), and intracellular adhesion molecule (ICAM)-1), free radical generation (xanthin oxidase), and NO regulation (iNOS). NF-kB is activated by various carcinogens and inflammatory stimuli, including cigarette smoke, TNF, IL-1, receptor activator of NF-kB ligand (RANKL), phorbol 12-myristate 13-acetate (PMA), and lipopolysccharide (LPS). NF-kB consists of p50 and p65 hetarodimer retained in the cytoplasm by masking NLS by its inhibitor IkBa. On activation, IkBa kinase (IKK) is activated, leading to IkBa phosphorylation, ubiquitination, and degradation, which releases p50-p65 to translocate to the nucleus, bind to its consensus sequence, and induce gene transcription. We hypothesized that zerumbone interferes with the NF-kB activation pathway and suppresses gene transcription. We tested this hypothesis by determining the effect of zerumbone on NF-kB and NF-kB-related gene expression activated by various inflammatory agents. Our results showed that zerumbone can indeed suppress the NF-kB activation induced by a wide variety of agents irrespective of cell type; it suppresses the expression of various antiapoptotic and proliferative gene products; it enhances apoptosis; and suppresses carcinogenesis induced by cytokines and chemotherapeutic agents.
Results
We investigated the effects of zerumbone on the NF-kB activation pathway induced by various carcinogens and inflammatory stimuli on NF-kB-regulated gene expression and on apoptosis induced by cytokines and chemotherapeutic agents. We focused on TNF-induced NF-kB activation because the TNF-induced NF-kB activation pathway had already been well characterized.
Zerumbone potentiates apoptosis induced by TNF and chemotherapeutic agents
The activation of NF-kB has been shown to inhibit TNF-induced apoptosis (Mayo et al., 1997; Verma and Stevenson, 1997; Giri and Aggarwal, 1998; Wang et al., 1998; Pomerantz and Baltimore, 2000) . Our results so far have suggested the potential of zerumbone to enhance the apoptosis induced by TNF and other cytotoxic agents through the suppression of NF-kBregulated antiapoptotic gene products. We investigated whether suppression of NF-kB by zerumbone affects TNF and chemotherapeutic agent-induced apoptosis with the Live/Dead assay and MTT assay methods PARP cleavage, annexin V staining, and TUNEL staining methods. The Live/Dead assay indicated that zerumbone upregulated TNF-induced cytotoxicity from 11 to 37% (Figure 1a) . Zerumbone also enhanced TNF-induced cytotoxicity analysed by the MTT method (Figure 1b1 ), as well as doxorubicin-and cisplatin-induced cytotoxicity (Figure 1b2 and 1b3, respectively). Zerumbone alone had little cytotoxicity at this concentration.
We showed that the enhanced cytotoxicity was due to apoptosis by using caspase-activated PARP cleavage. TNF-induced PARP-cleavage was enhanced in the zerumbone-treated cells (Figure 1c) , and annexin V staining indicated that zerumbone upregulates TNFinduced early apoptosis (Figure 1d ). TUNEL staining showed that TNF-induced apoptosis was enhanced by incubation with zerumbone ( Figure 1e) ; in this assay, zerumbone alone was slightly cytotoxic. The results of all the assays together suggest that zerumbone enhances the apoptotic effects of TNF and chemotherapeutic agents.
Zerumbone suppresses TNF-induced invasion activity
Tumor metastasis depends on the activity of MMPs, COX-2, and adhesion molecules (Liotta et al., 1982) . As previously stated, TNF can induce tumor metastasisrelated genes such as MMP-9, COX-2, and ICAM-1 (van de Stolpe et al., 1994; Yamamoto et al., 1995; Esteve et al., 2002) . Thus, we investigated whether zerumbone can modulate the tumor cell invasion activity induced by TNF in vitro. H1299 cells were seeded to the top chamber of the matrigel invasion chamber in the absence of serum, incubated with zerumbone, and then treated with TNF in the presence of 1% serum with zerumbone. Zerumbone suppressed TNF-induced invasion activity (2.6-fold) (Figure 2 ).
Zerumbone inhibits NF-kB activation induced by carcinogens and inflammatory stimuli As NF-kB plays an important role in apoptosis and in cell invasion, we examined the effect of zerumbone on Zerumbone inhibits NF-jB and NF-jB-mediated gene expression Y Takada et al the activation of this transcription factor. The structure of zerumbone and its homologue a-humulene are shown in Figure 3a and b, respectively. The latter lacks the a, b-unsaturated carbonyl group. TNF, okadaic acid, cigarette smoke condensate, PMA, and H 2 O 2 are potent activators of NF-kB but by different mechanisms (Pahl, 1999; Anto et al., 2002; Garg and Aggarwal, 2002; . Therefore, we examined the effect of zerumbone on the activation of NF-kB by these agents. Pretreatment of human lung carcinoma H1299 cells with zerumbone suppressed the activation of NF-kB induced by all five agents (Figure 3c ). These results suggest that zerumbone acts at a step in the NF-kB activation pathway that is common to all five agents.
Zerumbone-analogue, a-humulene, does not suppress NF-kB activation
The a-humulene zerumbone analogue, which lacks a carbonyl group at the 8-position in zerumbone, has been found to be inactive in suppressing free radical generation, cell proliferation, and apoptosis induction (Murakami et al., 2002) . Therefore, we examined whether a-humulene could affect TNF-induced NF-kB activation. Zerumbone completely suppressed TNFinduced NF-kB activation and a-humulene had no effect (Figure 3d ), suggesting that the zerumbone carbonyl group, which lacks in a-humalene, is needed for NF-kB activity.
Inhibition of NF-kB activation by zerumbone is not cell type specific Distinct signal transduction pathways can mediate NFkB induction in different cell types (Bonizzi et al., 1997; Ghosh and Karin, 2002) , so we investigated whether zerumbone could block TNF-induced NF-kB activation in human myeloid leukemia KBM-5 ( Figure 4a ) and human embryonic kidney A293 (Figure 4b ). TNF activated NF-kB in both cell types, and zerumbone completely inhibited the activation (Figure 4a, b) . These results indicated that there was a lack of cell type specificity.
Zerumbone inhibits constitutive NF-kB activation
Most tumor cells exhibit constitutive NF-kB activation. Therefore, we investigated whether zerumbone inhibits constitutive NF-kB in tumor cells in FaDu and LICR-LON-HN5 cells, which are known to express NF-kB constitutively, these cells were treated with different concentrations of zerumbone for 12 h and then analysed for NF-kB activation. Zerumbone inhibited the constitutive NF-kB activation in both cell lines in a dosedependent manner (Figure 4c, d ).
Zerumbone inhibits TNF-induced NF-kB activation in a dose-and time-dependent manner
Previous studies from our laboratory have shown that TNF can induce NF-kB activity more intensely at a high dose than at a lower dose given for a longer time (Chaturvedi et al., 1994) . To determine the effect of zerumbone on NF-kB activation when given at higher concentrations, we treated cells with various concentrations of TNF for 30 min in the absence or presence of a 24 h pretreatment with 50 mM zerumbone and then analysed NF-kB for activation by EMSA (Figure 5a ). Zerumbone by itself did not activate NF-kB, but TNFinduced NF-kB activation was inhibited by zerumbone in a dose-dependent manner (Figure 5b ), and a 50 mM dose of zerumbone completely abolished it. TNFinduced NF-kB activation was completely abolished by incubation with zerumbone for 24 h (Figure 5c ). Under those conditions, the cells were fully viable after the zerumbone treatment. Zerumbone inhibits NF-jB and NF-jB-mediated gene expression
At a concentration of 10 nM, TNF activated NF-kB strongly; zerumbone, however, abolished TNF-induced NF-kB activation. These results showed that zerumbone is a very potent inhibitor of TNF-induced NF-kB activation. To determine whether zerumbone directly modifies the binding of the NF-kB complex to DNA, as seen with caffeic acid phenethyl ester, chymotrypsinlike protease inhibitor N-tosyl-L-lysyl chloromethyl ketone and herbimycin (Higuchi et al., 1995; Mahon and O'Neill, 1995; Natarajan et al., 1996) , we incubated nuclear extracts from TNF-treated cells with various concentrations of zerumbone and then analysed the DNA binding activity by EMSA. Our results (Figure 5d ) showed that zerumbone did not modify the DNA binding ability of the NF-kB complex. We concluded that zerumbone inhibits NF-kB activation through an indirect, not direct, modification of the p65 subunit of NF-kB.
Since NF-kB is a complex of proteins, various combinations of Rel/NF-kB protein constitute the active NF-kB heterodimers that bind to specific DNA sequences (Ghosh and Karin, 2002) . To show that the retarded band visualized by EMSA in TNF-treated cells was indeed NF-kB, we incubated nuclear extracts from TNF-stimulated cells with antibodies to either the p50 (NF-kB1) or the p65 (RelA) subunit of NF-kB. Both shifted the band to a higher molecular mass (Figure 5e ), suggesting that the TNF-activated complex consisted of p50 and p65 subunits. Preimmune serum had no effect. Excess unlabeled NF-kB oligonucleotide caused a complete disappearance of the band, but a mutant oligonucleotide of NF-kB did not affect NF-kB binding activity.
Zerumbone inhibits TNF-dependent IkBa degradation
To determine whether the zerumbone inhibitory activity was due to inhibition of IkBa degradation, we pretreated cells with 50 mM zerumbone for 24 h and then exposed them to TNF. EMSA for NF-kB and Western blot analysis for IkBa status in the cytoplasm detected increase in activation of NF-kB as incubation times with TNF increased. Cells pretreated with zerumbone showed no activation of NF-kB, even after 60 min of TNF stimulation (Figure 6a ).
The translocation of NF-kB to the nucleus is known to proceed by the proteolytic degradation of IkBa (Ghosh and Karin, 2002) . TNF induced IkBa degrada- Zerumbone inhibits NF-jB and NF-jB-mediated gene expression Y Takada et al tion in the control cells within 10 min; in the zerumbonepretreated cells, however, TNF had no effect on IkBa degradation (Figure 6b , top panel). These results indicated that zerumbone inhibits both TNF-induced NF-kB activation and IkBa degradation.
Zerumbone inhibits TNF-dependent IkBa phosphorylation
To determine whether the inhibition of TNF-induced IkBa degradation was due to an inhibition of IkBa phosphorylation, we pretreated cells with zerumbone, exposed them to TNF, and then examined them for IkBa phosphorylation in the cytoplasm by Western blot analysis. TNF induced IkBa phosphorylation, and zerumbone almost completely suppressed it (Figure 6b , second panel).
Zerumbone inhibits TNF-induced phosphorylation of p65
TNF induces the phosphorylation of p65, which is required for its transcriptional activity (Ghosh et al., 1998) . After phosphorylation, the p65 subunit is translocated to the nucleus. TNF induced the phosphorylation of p65 ( Figure 6b , fourth panel); p65 was phosphorylated as soon as 5 min after TNF stimulation; the phosphorylation increased in the cytoplasm. After cells were pretreated with zerumbone, the TNF failed to induce p65 phosphorylation. We also determined the effect of zerumbone on the TNF-induced nuclear translocation of p65. TNF induced the translocation in a time-dependent manner, and zerumbone then suppressed it (Figure 6b , sixth panel). In the nuclear fraction from the TNF-treated cells, there was a timedependent increase in the phosphorylated form of p65, and zerumbone suppressed it (Figure 6b, seventh panel) .
The acetylation of p65 plays a key role in the transcriptional activity of NF-kB (Stancovski and Baltimore, 1997). Western blot analysis using an antiacetyl-lysine antibody showed that zerumbone suppressed TNF-induced p65 acetylation in a timedependent manner (Figure 6c ). Zerumbone inhibits NF-jB and NF-jB-mediated gene expression Y Takada et al
An immunocytochemistry assay confirmed the effect of zerumbone on the suppression of p65 nuclear translocation: in untreated cells p65 localized in the cytoplasm. TNF induced its nuclear translocation; and zerumbone clearly suppressed its translocation to the nucleus (Figure 6d ).
Zerumbone inhibits TNF-induced IKK activation
IKK is required for TNF-induced phosphorylation of IkBa (Ghosh and Karin, 2002) . Since zerumbone inhibits the phosphorylation of IkBa, we investigated the effect of zerumbone on TNF-induced IKK Zerumbone inhibits NF-jB and NF-jB-mediated gene expression Y Takada et al activation. We used the proteasome inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal, which blocks the degradation of IkBa (Vinitsky et al., 1992) . Immunocomplex kinase assays showed that TNF activated IKK as soon as 5 min after the TNF treatment and that the activation persisted for 30 min but that zerumbone pretreatment completely suppressed this activation (Figure 6e ). Neither TNF nor zerumbone had any effect on the expression of IKK-a or IKK-b proteins. An immunocomplex kinase assay showed that zerumbone had no direct effect on the activity of IKK, suggesting that zerumbone modulates TNF-induced IKK activation (Figure 6f ).
Zerumbone represses TNF-induced NF-kB-dependent reporter gene expression
As DNA binding alone does not always correlate with NF-kB-dependent gene transcription (Nasuhara et al., 1999) , we also investigated the effect of zerumbone on TNF-induced reporter gene transcription. To do so, we transiently transfected the cells with the NF-kB-regulated SEAP reporter construct, incubated them with zerumbone, and then stimulated them with TNF. The results showed that TNF activated the transcription of the reporter gene and that zerumbone completely inhibited it (Figure 7) . TNF-induced NF-kB activation is mediated through the sequential interaction of the TNF receptor with TRADD, TRAF2, NIK, and IKK, leading to the degradation of IkBa and p65 nuclear translocation (Hsu et al., 1996; Simeonidis et al., 1999) . Thus, we also investigated where in the pathway zerumbone suppresses gene transcription. To determine this, cells were transfected with TNFR 1-, TRADD-, TRAF2-, NIK-, IKK-, and p65 plasmids, along with the NF-kBregulated SEAP reporter construct, incubated with zerumbone, and then monitored for NF-kB-dependent SEAP expression. Zerumbone suppressed the NF-kB reporter activity induced by the TNFR 1-, TRADD-, TRAF2-, NIK-, and IKK plasmids but had no effect on the activity induced by the p65 plasmid (Figure 7) . These results suggest that zerumbone affects a step upstream of p65.
Zerumbone represses the TNF-induced NF-kB-dependent gene products involved in the proliferation and metastasis of tumor cells
We also investigated whether zerumbone can modulate NF-kB-regulated gene products involved in the proliferation and metastasis of tumor cells. TNF has been shown to induce cyclin D1, c-Myc, COX-2, MMP-9, and ICAM-1, all of which have NF-kB binding sites in their promoters (Duyao et al., 1992; van de Stolpe et al., 1994; Yamamoto et al., 1995; Guttridge et al., 1999; Esteve et al., 2002) . Thus, we investigated whether zerumbone inhibits the TNF-induced expression of these proteins. Cells untreated with zerumbone and those pretreated with zerumbone were examined for TNF-induced gene products by Western blot analysis using specific antibodies (Figure 8a) . TNF induced the expression of cyclin D1, c-Myc, COX-2, MMP-9, and ICAM-1 in a time-dependent manner, and zerumbone abolished it. These results further strengthen the role of zerumbone in blocking TNF-induced NF-kB-regulated gene products. (Tamatani et al., 1999) , Bfl-1/A1 (Grumont et al., 1999; Zong et al., 1999) , and FLIP (Kreuz et al., 2001) . We investigated whether zerumbone can modulate the expression of these antiapoptotic gene products induced by TNF. TNF induced the activity of these antiapoptotic proteins in a time-dependent manner, and zerumbone blocked it (Figure 8b ).
Discussion
The goal of this study was to determine whether the antiinflammatory and antiproliferative effects of zerum- Zerumbone inhibits NF-jB and NF-jB-mediated gene expression Y Takada et al bone were mediated through modulation of NF-kB and NF-kB regulated gene products involved in inflammation, proliferation, and apoptosis. We found that zerumbone suppressed NF-kB activation induced by various carcinogens and inflammatory agents irrespective of cell type. NF-kB inhibition correlated with IKK suppression, IkBa phosphorylation and degradation, and p65 phosphorylation, nuclear translocation, and acetylation. Zerumbone also downregulated NF-kBdependent gene products involved in cell proliferation (e.g. cyclin D1 and c-Myc), in antiapoptosis (e.g. survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-x L , Bfl-1/A1, and FLIP), and in invasion (MMP-9, COX-2, and ICAM-1). This downregulation led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents and to a suppression of invasion. Zerumbone's inhibition of the NF-kB activation induced by TNF, okadaic acid, cigarette smoke condensate, PMA, and H 2 O 2 suggests that zerumbone acts at a step common to all of these activators. In response to most of these stimuli, NF-kB activation requires the activation of IKK. Zerumbone's suppression of TNF-induced IKK activation suggests that zerumbone suppresses NF-kB activation by other agents through a suppression of IKK activation. We showed that suppression of IKK leads to the inhibition of IkBa phosphorylation and degradation. These results are consistent with those from a previous study that showed that zerumbone can suppress IkBa degradation in RAW 264.7 cells activated by LPS and IFN-g (Murakami et al., 2003b) .
We also found that zerumbone inhibited NF-kBregulated gene transcription and the NF-kB-regulated gene products involved in cell proliferation (e.g. cyclin D1 and c-Myc), antiapoptosis (e.g. survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-x L , Bfl-1/A1, and FLIP), and invasion (MMP-9, COX-2, and ICAM-1). In agreement with previous studies, our results indicate that zerumbone can suppress COX-2 expression induced by LPS/IFN-g in mouse macrophages (Murakami et al., 2003b) and by DMBA/TPA in mice skins (Murakami et al., 2004) .
Our results may also explain zerumbone's downregulation of TNF, IL-1b, and iNOS (Murakami et al., 2002) , all known to be regulated by NF-kB. However, we are the first to report the ability of zerumbone to modulate expression of other gene products. cyclin D1, which is required for G 1 -to-S-phase transition of the cell cycle (Weinstein, 2000) , is overexpressed in a wide variety of tumor cells . Thus, the downregulation of cyclin D1 by zerumbone may explain the antiproliferative effects of zerumbone on breast and colon cancer cells (Murakami et al., 2002; Kirana et al., 2003) .
Xanthine oxidase is one of the major sources of superoxide radical production in cells. This enzyme is regulated by NF-kB (Xu et al., 1996) . Zerumbone's suppression of superoxide radical production (Murakami et al., 2002) could be due to the downregulation of this enzyme's expression.
We found that zerumbone downregulated TNFinduced expression of the antiapoptosis gene products survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP. This downregulation correlated with the potentiation of the apoptotic effects of cytokines and chemotherapeutic agents. The cytotoxic effects of TNF, doxorubicin, and cisplatin were enhanced by zerumbone.
We also found that zerumbone downregulated the expression of MMP-9, COX-2, and ICAM-1. This downregulation correlated with the inhibition of TNFinduced invasion by zerumbone. MMP-9 plays a crucial role in tumor invasion and angiogenesis by mediating the degradation of the extracellular matrix, and the inhibition of MMP activity has been shown to suppress lung metastasis (Shiraga et al., 2002) . COX-2 also has been implicated in carcinogenic processes, and its overexpression by malignant cells has been shown to enhance cellular invasion, induce angiogenesis, regulate antiapoptotic cellular defenses, and augment immunologic resistance through the production of PGE-2 (Hirschowitz et al., 2002) . Adhesion molecules such as ICAM-1 play an essential role in the adhesion of tumor cells to endothelial cells and thus mediate tumor cell metastasis. Several chemokines, interleukins, and hematopoietic growth factors are regulated by NF-kB activation (Garg and Aggarwal, 2002) . Murakami et al. (2002) reported that zerumbone suppresses the expression of the inflammatory cytokines TNF and IL-1b in LPS/IFN-g-treated mouse macrophages and in dextran sodium sulfate-induced colitis in mice (Murakami et al., 2003a) , these cytokines are also regulated by NF-kB (Shakhov et al., 1990; Hiscott et al., 1993) . On the basis of our findings, we conclude that zerumbone is a potent inhibitor of NF-kB and NF-kB-regulated gene products and that this inhibition may explain its antiproliferative and antiinflammatory effects.
Materials and methods

Reagents
A 25 mM solution of zerumbone was prepared with dimethyl sulfoxide, stored as small aliquots at À201C and then diluted as needed in cell culture medium. a-Humulene was purchased from MP Biomedicals (Irvine, CA, USA). Bacteria-derived human recombinant human TNF, purified to homogeneity with a specific activity of 5 Â 10 7 U/mg, was kindly provided by Genentech (South San Francisco, CA, USA). Cigarette smoke condensate, prepared as previously described (Anto et al., 2002) , was kindly supplied by Dr C Gary Gairola (University of Kentucky, Lexington, KY, USA). Penicillin, streptomycin, RPMI 1640 medium, and FBS were obtained from Invitrogen (Grand Island, NY, USA). PMA, okadaic acid, H 2 O 2 , and anti-b-actin antibody were obtained from Aldrich-Sigma (St Louis, MO, USA). Antibodies against p65, p50, IkBa, cyclin D1, MMP-9, ICAM-1, c-Myc, PARP, IAP1, IAP2, Bcl-2, Bcl-x L , TRAF1, and Bfl-1/A1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-COX-2 and anti-XIAP antibodies were obtained from BD Biosciences (San Diego, CA, USA). Phospho-specific anti-IkBa (Ser32), phosphospecific anti-p65 (Ser536), and antiacetyl-lysine antibodies were purchased from Cell Signaling (Beverly, MA, USA).
Anti-IKK-a, anti-IKK-b, and anti-FLIP antibodies were kindly provided by Imgenex (San Diego, CA, USA).
Cell lines
Cell lines H1299 (lung adenocarcinoma), KBM-5 (human myeloid), A293 (human embryonic kidney), and FaDu (human squamous cell carcinoma) cells were obtained from American Type Culture Collection (Manassas, VA, USA). LICR-LON-HN5 (human squamous cell carcinoma) cells were obtained from Dr MJ O'Hare (Haddow Labs., Institute of Cancer Research, Sutton, Surrey, UK). The H1299 cells were cultured in RPMI 1640 medium, the KBM-5 cells were cultured in IMDM medium with 15% FBS, the A293 cells were cultured in DMEM medium supplemented with 10% FBS, and the LICR-LON-HN5 cells were cultured in DMEM containing 10% FBS, 100 mM nonessential amino acids, 1 mM pyruvate, 6 mM L-glutamine, and 1 Â vitamins. All culture media were also supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin.
Electrophoretic mobility shift assays (EMSA)
To determine NF-kB activation, we prepared the nuclear extracts and performed EMSA as described previously . For supershift assays, nuclear extracts prepared from TNF-treated cells were incubated with antibodies against either p50 or p65 of NF-kB for 15 min at 371C before the complex was analysed by EMSA. Preimmune serum was included as the negative control. The dried gels were visualized, and the radioactive bands quantitated with a Storm820 and Imagequant software (Amersham, Piscataway, NJ, USA).
Western blot analysis
To determine the levels of protein expression in the cytoplasm and the nucleus, we prepared extracts and fractionated them by SDS-polyacrylamide gel electrophoresis (PAGE). After electrophoresis, the proteins were electrotransferred onto nitrocellulose membranes, blotted with each antibody, and detected by an ECL regent (Amersham). The bands obtained were quantitated using the NIH image (National Institues of Health, NIH, Bethesda, MD, USA).
IKK assay
To determine the effect of zerumbone on TNF-induced IKK activation, an IKK assay was performed by a method described previously . Briefly, the IKK complex from whole-cell extracts was precipitated with antibody against IKK-a and then treated with protein A/GSepharose beads (Pierce, Rockford, IL, USA). After 2 h, the beads were washed with lysis buffer and then resuspended in a kinase assay mixture containing 50 mM HEPES, pH 7.4, 20 mM MgCl 2 , 2mM DTT, 20 mCi [g-32 P]ATP, 10 mM unlabeled ATP, and 2 mg of substrate GST-IkBa (aa 1-54). After incubation at 301C for 30 min, the reaction was terminated by boiling with SDS sample buffer for 5 min. Finally, the protein was resolved on 10% SDS-PAGE, the gel was dried, and the radioactive bands were visualized with a Storm820. To determine the total amounts of IKK-a and IKK-b in each sample, 50 mg of whole-cell proteins was resolved on 7.5% SDS-PAGE, electrotransferred onto a nitrocellulose membrane, and then blotted with either anti-IKK-a or anti-IKK-b antibody.
NF-kB-dependent reporter gene expression assay
To determine the effect of zerumbone on TNF-, TNFR-, TRADD-, TRAF2-, NIK-, IKK-, and p65-induced NF-kBdependent reporter gene transcription, we performed the secretory alkaline phosphatase (SEAP) assay as previously described. Briefly, H1299 cells (5 Â 10 5 cells/well) were plated in six-well plates and transiently transfected by Fugene6 (Roche Molecular Biochemicals, Mannheim, Germany) with pNF-kB-SEAP (0.25 mg). To examine TNFinduced reporter gene expression, we transfected the cells with 0.25 mg of the SEAP expression plasmid with 1 mg of the control plasmid, pCMVFLAG1, for 24 h. We treated the cells for 12 h with 25 mM zerumbone and then stimulated them with 1 nM TNF for further 24 h. To examine the expression levels of various gene-induced reporter genes, the cells were transfected with 0.25 mg of reporter gene plasmid with each 1 mg of expressing plasmid for 24 h and then treated with 25 mM zerumbone for 36 h. The cell culture medium was harvested and analysed for SEAP activity according to the protocol, essentially in the same way described by the manufacturer (Clontech, Palo Alto, CA, USA) using Victor 3 microplate reader (Perkin-Elmer Life and Analytical Sciences, Boston, MA, USA).
Immunoprecipitation of p65 for p65 acetylation
To determine the effect of zerumbone on TNF-induced acetylation of p65, TNF-treated cell extracts were immunoprecipitated with anti-p65 antibody, resolved on SDS-PAGE, and then blotted with antiacetyl-lysine antibody. Cells (3 Â 10 6 ) were treated and washed with ice-cold phosphatse-buffered saline (PBS) and then lysed in a buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EGTA, 2 mM NaF, 10% glycerol, 0.2% Triton X-100, 0.2 mM sodium orthovanadate, 2 mg/ml aprotinin, and 2 mg/ml leupeptin to prepare whole-cell lysates. Whole-cell extracts were incubated with anti-p65 antibody for 2 h and precipitated using protein A/G sepharose beads. After 1 h of incubation, the immunocomplex was washed with lysis buffer, boiled with an SDS sample buffer for 5 min, fractionated on SDS-PAGE, and then subjected to Western blot analysis with an antiacetyl-lysine antibody.
Immunocytochemistry for NF-kB p65 localization
Immunocytochemistry was used to examine the effect of zerumbone on the nuclear translocation of p65 as previously described . Briefly, the cells were seeded in a chamber slide (Lab-Tek II Chamber Slide System, Nalge Nunc International, Rochester, NY, USA), treated, airdried, and fixed with 4% paraformaldehyde after permeabilization with 0.2% of Triton X-100. After being washed in PBS, the slides were blocked with 5% normal goat serum for 1 h and then incubated with rabbit polyclonal antihuman p65 antibody at a 1 : 200 dilution. After overnight incubation at 41C, the slides were again washed, incubated with goat anti-rabbit IgG-Alexa 594 at a 1 : 200 dilution for 1 h, and the nuclei were counterstained with Hoechst 33342 (50 ng/ml) for 5 min. The stained slides were mounted with a mounting medium purchased from Aldrich Sigma and analysed under a fluorescence microscope (Labophot-2, Nikon, Tokyo, Japan). Pictures were captured using a Photometrics Coolsnap CF color camera (Nikon, Lewisville, TX, USA) and MetaMorph version 4.6.5 software (Universal Imaging, Downingtown, PA, USA).
Live/Dead assay
To measure apoptosis, we also used the Live/Dead assay (Molecular Probes, Eugene, OR, USA), which determines intracellular esterase activity and plasma membrane integrity. This assay uses calcein, a polyanionic dye, which is retained within the live cells and provides green fluorescence. It also uses the ethidium monomer dye (red fluorescence), which can enter the cells only through damaged membranes; it can bind to nucleic acids but is excluded by the intact plasma membrane of live cells. Briefly, the cells were seeded in a chamber slide (Nalge Nunc International), incubated with 50 mM zerumbone for 12 h, and then treated with 1 nM TNF for 16 h at 371C. The cells were stained with the Live/Dead reagent (5 mM ethidium homodimer, 5 mM calcein-AM) and then incubated at 371C for 30 min. The cells were analysed under a fluorescence microscope (Labophot-2).
Cytotoxicity assay
The effects of zerumbone on the cytotoxic effects of TNF and two chemotherapeutic agents were determined by the MTT uptake method as previously described (Shishodia et al., 2003) . Briefly, 10 000 cells were incubated with 5 mM zerumbone for 12 h in triplicate in a 96-well plate and then treated with the indicated concentrations of TNF, doxorubicin, or cisplatin for 24 h at 371C. An MTT solution was added to each well and incubated for 2 h at 371C. An extraction buffer (20% SDS, 50% dimethylformamide) was added, and the cells were incubated overnight at 371C. Then the optical density was measured at 570 nm using a 96-well multiscanner (Dynex Technologies, MRX Revelation; Chantilly, VA, USA).
Annexin V assay
An early indicator of apoptosis is the rapid translocation and accumulation of the membrane phospholipid phosphatidylserine from the cytoplasmic interface of membrane to the extracellular surface. This loss of membrane asymmetry can be detected by using the binding properties of annexin V. To identify apoptosis, we used an annexin V antibody, which was conjugated with the fluorescein isothiocyanate fluorescence dye. Briefly, 5 Â 10 5 cells were pretreated with 50 mM zerumbone for 12 h, treated with 1 nM TNF for 16 h at 371C, and subjected to annexin V staining. The cells were washed in PBS, resuspended in 100 ml of binding buffer containing a fluorescein isothiocyanate-conjugated anti-annexin V antibody, and then analysed with a flow cytometer (FACSCalibur, BD Biosciences).
TUNEL assay
We also assayed cytotoxicity by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick endlabeling (TUNEL) method, which examines DNA-strand breaks during apoptosis with an in situ cell death detection reagent (Roche). Briefly, 5 Â 10 5 cells were incubated with 50 mM zerumbone for 24 h and then treated with 1 nM TNF for 16 h at 371C. The cells were trypsinized, fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. After being washed, the cells were incubated with the reaction mixture for 60 min at 371C. The stained cells were analysed with a flow cytometer (FACSCalibur).
Invasion assay
The membrane invasion culture system was used to measure cell invasion. Invasion through the extracellular matrix is a crucial step in tumor metastasis. Matrigel basement membrane matrix extracted from the Engelbreth-Holm-Swarm mouse tumor was used as the reconstituted basement membrane to provide a biologically active extracellular matrix for the in vitro invasion assays. The BD BioCoat tumor invasion system (BD Biosciences), which has a chamber with a light-tight polyethylene terephthalate membrane containing an 8-mm pore, was coated with a reconstituted basement membrane gel (BD Biosciences). Subsequently, 2.5 Â 10 4 cells were resuspended in serum-free medium and seeded into the upper wells. After incubation overnight, the cells were treated with 25 mM zerumbone for an additional 12 h and then stimulated with 1 nM TNF for 24 h more in the presence of 1% FBS and 25 mM zerumbone. The cells that invaded through the matrigel were labeled with 4 mg/ml calcein acetoxymethylester (Molecular Probes) in PBS for 30 min at 371C and subjected to scan fluorescence with a Victor 3.
Abbreviations NF-kB, nuclear factor-kB; IkB, inhibitory subunit of NF-kB; IKK, IkBa kinase; NIK, NF-kB-inducing kinase; TNF, tumor necrosis factor; SEAP, secretory alkaline phosphatase; PMA, phorbol myristate acetate; TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick endlabeling; IL, interleukin; FADD, Fas-associated death domain protein; FLICE, FADD-like interleukin-1b-converting enzyme; FLIP, FLICE-inhibitory protein; COX, cyclooxygenase; MMP, matrix metalloproteinase; TRAF, TNF receptorassociated factor; PBS, phosphate-buffered saline.
